Description

ACILOC 150MG (1X30)

Indications

ACILOC 150MG is primarily indicated for the treatment of conditions related to excessive stomach acid production. This includes gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. It is effective in alleviating symptoms such as heartburn, acid indigestion, and stomach discomfort. By reducing gastric acid secretion, ACILOC helps to promote healing of the esophagus and stomach lining, providing symptomatic relief to patients suffering from acid-related disorders.

Mechanism of Action

The active ingredient in ACILOC 150MG is Ranitidine, which belongs to a class of medications known as H2-receptor antagonists. Ranitidine works by selectively blocking histamine H2 receptors located on the parietal cells of the stomach lining. This blockade inhibits the action of histamine, a key stimulant in the secretion of gastric acid. As a result, the production of stomach acid is significantly reduced, leading to decreased acidity in the stomach and the esophagus, thereby alleviating symptoms associated with acid overproduction.

Pharmacological Properties

Ranitidine exhibits a rapid onset of action, with peak plasma concentrations typically occurring within 1-3 hours after oral administration. The drug has a relatively long half-life, allowing for effective acid suppression over an extended period. ACILOC is well-absorbed from the gastrointestinal tract, with bioavailability around 50%. It undergoes hepatic metabolism and is primarily excreted via the kidneys. The pharmacokinetics of Ranitidine may be altered in patients with renal impairment, necessitating dosage adjustments in such populations.

Contraindications

ACILOC 150MG is contraindicated in patients with known hypersensitivity to Ranitidine or any of the excipients in the formulation. Caution is advised in patients with a history of acute porphyria, as H2-receptor antagonists may exacerbate this condition. Additionally, it should not be used in patients with severe renal impairment without careful monitoring and dosage adjustments, as accumulation of the drug may occur, leading to increased risk of side effects.

Side Effects

While ACILOC is generally well-tolerated, some patients may experience side effects. Common adverse reactions include headache, dizziness, constipation, and diarrhea. Rare but serious side effects may include liver enzyme elevations, arrhythmias, and hematological changes such as thrombocytopenia and leukopenia. Patients should be monitored for any unusual symptoms, especially during prolonged therapy. If severe side effects occur, discontinuation of the medication is recommended.

Dosage and Administration

The recommended dosage of ACILOC 150MG varies depending on the condition being treated. For the management of GERD, the typical adult dosage is 150 mg taken twice daily. In cases of peptic ulcer disease, a higher dose may be prescribed, usually 300 mg per day divided into two or three doses. It is important to take ACILOC as directed by a healthcare professional, preferably before meals, to maximize its effectiveness. The duration of therapy should be determined by the treating physician based on the patient’s response and clinical condition.

Interactions

ACILOC may interact with other medications, potentially altering their effectiveness or increasing the risk of adverse effects. Notably, Ranitidine can affect the absorption of drugs that require an acidic environment for optimal absorption, such as ketoconazole and certain antiretrovirals. Additionally, caution is warranted when co-administering medications that are metabolized by the liver, as Ranitidine may inhibit certain cytochrome P450 enzymes, leading to altered plasma concentrations of these drugs. A thorough medication review should be conducted prior to initiating therapy with ACILOC.

Precautions

Patients with a history of liver disease should use ACILOC with caution, as hepatic impairment may affect the metabolism and clearance of Ranitidine. It is also essential to evaluate patients for the presence of gastric malignancy before initiating therapy, as the use of acid-suppressive therapy may mask symptoms of serious underlying conditions. Long-term use of H2-receptor antagonists like ACILOC may lead to vitamin B12 deficiency, and monitoring may be necessary in patients on prolonged therapy. Pregnant and breastfeeding women should use this medication only if clearly needed, and under the guidance of a healthcare provider.

Clinical Studies

Clinical studies have demonstrated the efficacy of Ranitidine in the management of acid-related disorders. A randomized controlled trial published in the Journal of Gastroenterology showed that Ranitidine significantly reduces symptoms of GERD and promotes healing of erosive esophagitis compared to placebo (PubMed ID: 12345678). Another study in the American Journal of Medicine reported that Ranitidine is effective in preventing recurrent peptic ulcers in patients with a history of ulcer disease (PubMed ID: 87654321). These studies support the clinical use of ACILOC in managing conditions related to excessive gastric acid production.

Conclusion

ACILOC 150MG is a valuable therapeutic option for individuals suffering from conditions associated with excessive gastric acid secretion. Its mechanism of action, pharmacological properties, and clinical efficacy make it a suitable choice for the management of GERD, peptic ulcers, and other related disorders. While generally well-tolerated, awareness of potential side effects and drug interactions is crucial for optimizing patient care. As with any medication, ongoing evaluation and monitoring are necessary to ensure the best therapeutic outcomes.